http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
강예림,전병우,전경만,고원중,서지영,정만표,김호중,권오정,한정호,엄상원 대한결핵및호흡기학회 2011 Tuberculosis and Respiratory Diseases Vol.71 No.5
Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a useful, safe diagnostic modality for evaluating mediastinal and hilar lymphadenopathy. We report a 51-year-old male who presented with a left renal mass and multiple pleural masses without lung parenchymal lesions. The pleural masses were thought to be metastatic tumors or malignant mesothelioma. The patient underwent two percutaneous needle biopsies of the pleural mass, but the specimens were insufficient for a histopathological diagnosis. Because one pleural mass was adjacent to the right main bronchus, we decided to perform EBUS-TBNA for the pleural mass. As a result, sufficient core tissue was obtained with no complications, and the histopathological findings were consistent with metastatic papillary renal cell carcinoma. To our knowledge, this is the first case of using EBUS-TBNA for a pleural mass.
강예림 ( Yeh Rim Kang ),이정우 ( Jung Woo Lee ),전희정 ( Hee Jung Jeon ),이신엽 ( Shin Yeop Lee ),차승익 ( Seung Ick Cha ),박태인 ( Tae Ihn Park ),박재용 ( Jae Yong Park ),정태훈 ( Tae Hoon Jung ),김창호 ( Chang Ho Kim ) 대한결핵 및 호흡기학회 2009 Tuberculosis and Respiratory Diseases Vol.66 No.1
Dieulafoy`s disease of the bronchus is rare but potentially life-threatening, and should be considered in patients with massive hemoptysis, especially from unknown etiology. We report a case of a patient with massive hemoptysis due to bronchial Dieulafoy`s disease. He underwent bronchial artery embolization and surgical resection, and the post-operative specimen revealed dilated and tortuous arteries in the submucosa that presented as Dieulafoy`s disease of the bronchus.
우리나라의 건강보험 약가 사후관리제도 고찰 및 발전 방안
강예림(Ye Rim Kang),고소희(So Hee Ko),이종혁(Jong Hyuk Lee) 대한약학회 2017 약학회지 Vol.61 No.1
This study examines post-listing control systems for pharmaceutical pricing and suggests a reasonable improvement policy in Korea. There are four post-listing control systems for pharmaceutical pricing in Korean national health insurance. When each scheme was introduced, they had their own background and goals. But it is very difficult to understand and predict the timing and extent of the price cuts due to complex system by introducing or revising some schemes without clear policy objectives. At the same time, the social costs are often caused by various confusions, including distribution sites, due to frequent price cuts. For this reason, the current post-listing control system needs to be improved. We investigated the latest trends of the post-listing control system of the major countries that operate a similar system through literatures, website, reports of relevant institutions. From a mid- to long-term point of view, the system should be that can enhance the health of the population by comprehensively reflecting drug prescribing behavior and use status under clear target for drug expenditure management. It should also be developed as a system that can create a healthy industrial ecosystem for the development of the pharmaceutical industry.